Hamilton James C 4

What Happened
James C. Hamilton, Chief Medical Officer of Arrowhead Pharmaceuticals (ARWR), sold 10,000 shares of common stock in an open-market sale on April 23, 2026. The reported proceeds were about $750,000 — the filing reports a weighted average price of $75.00 and notes trades executed in the $75.00–$75.13 range. This was a sale (not a purchase); sales under pre-established plans are often routine and do not necessarily signal a change in the insider’s view.

Key Details

• Transaction date: 2026-04-23; Form 4 filed: 2026-04-24 (transaction reported promptly).
• Shares sold: 10,000; reported weighted average price: $75.00; price range across trades: $75.00–$75.13; total proceeds ≈ $750,000.
• Footnotes of note:
  • F1: Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  • F2: Weighted average price shown; reporting person can provide a breakdown of shares sold at each price within the stated range upon request.
  • F3: Beneficial ownership figures reported on the form include previously reported shares underlying restricted stock units (some of which remain subject to vesting).
• Shares owned after the transaction are not specified in the provided summary of the filing.

Context
A 10b5-1 plan allows insiders to schedule trades in advance and is commonly used to avoid questions about timing; sales under such plans are generally viewed as routine rather than a direct indicator of the insider’s current sentiment. For retail investors, purchases by insiders typically carry more weight as a bullish signal; disclosed sales should be noted but interpreted cautiously and in the context of broader company news and fundamentals.